| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |







From the Department of Pathology,*MD Anderson Cancer Center, Houston, Texas; the Department of Pathology, The Johns Hopkins University School of Medicine,
Baltimore, Maryland; and the Departments of Internal Medicine
and Pathology,
Chonnam National University Medical School, Kwangju, South Korea
| Abstract |
|---|
|
|
|---|
There are two major histological types of gastric adenocarcinoma (intestinal and diffuse) according to the Lauren classification.14 The pathogenesis and genetic alterations for these two distinct types of adenocarcinoma are also different.15-17 The most frequent gastric malignancy is the intestinal type, which is often preceded by sequential steps of precancerous changes, including atrophic gastritis, intestinal metaplasia, and either dysplasia or adenoma. In contrast, the diffuse type of gastric carcinoma tends to arise de novo and is infrequently associated with dysplasia or adenoma.18-21 Abnormal expression and amplification of the Met gene, inactivation of the p53 tumor suppressor gene, abnormal transcription of CD44, and loss of telomerase are common events in both types.15-17,22,23 Reduced or absent expression of E-cadherin and K-sam gene amplification are unique to the diffuse type gastric adenocarcinoma.16,17,22 By contrast, K-ras mutations, c-erb2 gene amplification, mutations of the APC gene, allelic loss of BclII gene and DCC locus, and microsatellite instability (MSI, replication error) are preferentially associated with the intestinal-type.16,17,22 Gastric adenoma (polypoid dysplastic mucosal lesion) and flat dysplasia have been regarded as precancerous lesions for intestinal type adenocarcinoma. The sequential accumulation of alternations of APC and K-ras genes, characteristic of the colorectal adenoma-carcinoma sequence, however, does not frequently occur between adenoma and intestinal-type adenocarcinoma of the stomach.3-7,24-26
There are two lines of evidence indicating that not all gastric dysplastic lesions are precursor lesions for gastric carcinoma. First, gastric dysplasia can undergo spontaneous regression clinically, especially low-grade dysplastic lesions.27,28 Only 11 to 40% of adenoma/dysplasia progress to carcinoma.29-31 Secondly, APC mutations have been reported to occur more frequently in gastric adenomas than in gastric adenocarcinomas.24-26 However, the APC mutation status of gastric adenoma/dysplasia lesions associated with adenocarcinomas has not been studied in detail. It is not clear whether the APC gene plays any role in the pathogenesis of adenocarcinomas arising from pre-existing adenoma/dysplasia. Furthermore, genetic alterations separating these two distinct morphological precancerous lesions (flat dysplasia and polypoid adenoma) remain unclear. In this study, we investigated genetic alterations in gastric adenomas, flat dysplasias, adenocarcinoma with associated adenoma/dysplasia, and adenocarcinoma without associated adenoma/dysplasia to determine their potential roles in gastric carcinogenesis.
| Materials and Methods |
|---|
|
|
|---|
This study included 35 adenomas and 47 flat dysplasias from endoscopic biopsies of patients without gastric carcinoma, 39 adenocarcinomas (20 diffuse type and 19 intestinal type) without an associated adenoma/dysplasia, and 35 adenocarcinomas associated with adenoma/dysplasia (29 adenomas/dysplasias were immediately adjacent to the carcinoma, and 6 were distant) from surgical resection specimens (approved by University of Texas MD Anderson Cancer Center Institutional Review Board). All of the cases were retrospectively identified from the surgical pathology files of Chonnam National University Hospital, Kwangiu, South Korea between 1996 to 2000. No patient had familial adenomatous polyposis (FAP). The distinction between adenoma and dysplasia was based on endoscopic findings. Gastric adenoma was defined as a polypoid, elevated or exophytic lesion, and flat dysplasia as a flat or depressed lesion. Gastric adenomas and dysplasias were subclassified in hematoxylin and eosin (H&E)-stained slides into low-grade and high-grade dysplasia according to published criteria.32
The carcinomas were classified histologically according to Lauren14
and staged according to the criteria of the International Union Against Cancer.33
Location and size of tumor were also recorded. Gastric nonneoplastic mucosa was evaluated for the presence of intestinal metaplasia, mucosal atrophy by Sydney criteria, and Helicobacter pylori by Giemsa stain and Campylobacter-like organism (CLO) test.34
The clinicopathogical features of patients are summarized in Table 1
. Most of adenocarcinomas associated with adenoma/dysplasia were stage 1 tumors and intestinal type carcinomas.
|
Microdissection from formalin-fixed and paraffin-embedded tissue was performed on H&E-stained slides for both tumor and normal mucosa. A 271/2-gauge needle was used for microdissection of H&E-stained slides under a low-power (x4) objective. In cases of adenocarcinoma associated with adenoma/dysplasia, carcinoma and adenoma/dysplasia components were separately microdissected and analyzed. Genomic DNA was extracted from microdissected tissue as described previously.35
APC Gene Mutation Analysis
Four sets of oligonucleotide primers (5'-CAGACTTATTGTGTAGAAGA-3' and 5'-CTCCTGAAGAAAATTCAACA-3' for codons 1260 to 1350; 5'-AGGGTTCTAGTTTATCTTCA-3' and 5'-TCTGCTTGGTGGCATGGTTT-3' for codons 1339 to 1436; 5'-GGCATTATAAGCCCCAGTGA-3' and 5'-AAATGGCTCATCGAGGCTCA-3' for codons 1417 to 1516; 5'-ACTCCAGATGGATTTTCTTG-3' and 5'-GGCTGGCTTTTTTGCTTTAC-3' for codons 1497 to 1596) were used to amplify the mutation cluster region of the APC gene for gastrointestinal tumors. Polymerase chain reaction (PCR) was performed under standard conditions in a 50-µl volume using PCR Master (Boehringer Mannheim, Mannheim, Germany) and 1 µmol/L of both 5' and 3' oligonucleotides with 40 cycles (94°C for 1 minute, 58°C for 1 minute, and 72°C for 2 minutes). PCR products were purified using shrimp alkaline phosphatase and exonuclease I (Amersham, Buckinghamshire, UK). Purified PCR products were sequenced directly with SequiTherm Excel II DNA Sequencing Kit (Epicentre, Madison, WI) with the same primers used for DNA amplification. Oligonucleotides were end-labeled with [
-32P]-ATP (DuPont-New England Nuclear Research Products, Boston, MA) using T4 polynucleotide kinase (New England Biolabs, Beverly, MA). All mutations were verified in both the sense and anti-sense directions.
ß-Catenin Gene Mutation Analysis
Mutation analysis of the ß-catenin gene was performed only on cases that did not show detectable APC mutations. Genomic DNA from each sample was amplified by PCR using the forward primer 5'-ATGGAACCAGACAGAAAAGC-3' and reverse primer 5'-GCTACTTGTTCTTGAGTGAAG-3'. These amplified a 200-bp fragment of exon 3 of the ß-catenin gene encompassing the region for GSK-3ß phosphorylation. PCR reaction was performed under standard conditions in a 50 µl volume using PCR Master (Boehringer Mannheim) and 1 µmol/L of both 5' and 3' oligonucleotides with 40 cycles (94°C for 1 minute, 58°C for 1 minute, and 72°C for 2 minutes). PCR products were purified and sequenced directly using internal primers (forward, 5'-AAAGCGGCTGTTAGTCACTGG-3'; reverse, 5'-CCTGTTCCCACTCATACAGG-3') as described above. All mutations were verified in both the sense and anti-sense directions.
K-ras Oncogene Mutation Analysis
The first exon of K-ras was amplified in a 50-µl volume using the reaction mixture described above with oligonucleotide primers (5'-GGCCGGTAGTGTATTAACCTTATGTGTGACAT-3' and 5'-CCGCGGCCGGCGGCCAAAACAAGATTTACCTCTATTGTTGG-3'). PCR products were purified as described. The purified PCR products were sequenced using ABI PRISM BigDye Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) with an internal primer 5'-ATTCGTCCACAAAATGAT-3'. The sequencing reactions were run on an ABI PRISM 3700 DNA Analyzer (Applied Biosystems). The data were collected and analyzed using Applied Biosystems sequencing software, according to the manufacturers protocols.
Microsatellite Instability Analysis
MSI status was determined by five fluorescently labeled PCR amplifications using fluorescent dye-labeled forward primer and unlabeled reverse primer (BAT-25, BAT-26, D2S123, D5S346, and D17S250). The forward oligonucleotide was end-labeled with 6-FAM (Applied Biosystems). PCR was performed in 15-µl volumes containing 40 ng of DNA, 9 µl ABI Prism True Allele PCR Premix (Applied Biosystems), 5 pmol of 6-FAM-labeled forward primer, and 10 pmol of unlabeled reverse primer. PCR was performed using the following cycling conditions: denaturation at 95°C for 6 minutes, 45 cycles of 94°C for 45 seconds, 55°C for 45 seconds, 72°C for 1 minute, and extension at 72°C for 30 minutes. The PCR product was diluted further with 30 µl of H2O, and a 1.0 µl aliquot of each diluted fluorescent-labeled PCR product was combined with 12 µl of formamide and 0.5 µl of Genescan 400HD (ROX) size standard (Applied Biosystems). The samples were then capillary electrophoresed on an ABI 3700 DNA Analyzer using GeneScan Analysis software (Applied Biosystems). Allelic shift (MSI) of a microsatellite marker was defined by the presence of at least one additional band in the DNA from tumor or invasive carcinoma that was not present in the control normal DNA. A specimen was considered as MSI-high (MSI-H) when at least two markers showed allelic shift or MSI-low (MSI-L) when only one marker was shifted.
Statistical Analysis
Fishers exact test was used to compare differences in clinical or pathological characteristics, gene mutation, and MSI phenotype. A P value of <0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
Somatic APC mutations were more frequent in gastric adenomas and flat dysplasia without carcinoma (76%, 59 of 78) than in adenocarcinomas (4%, 3 of 69; P < 0.000001) or in adenomas/dysplasias associated with adenocarcinoma (3%, 1 of 30; P < 0.000001) (Table 2)
. There was no difference in the APC mutation rate between polypoid adenomas (77%, 24 of 31) and flat dysplasias (74%, 35 of 47). Similarly, there was no difference in the APC mutation rate between adenocarcinomas associated with adenoma/dysplasia (7%, 2 of 30) and adenocarcinomas without associated adenoma/dysplasia (3%, 1 of 39). Two adenocarcinomas associated with adjacent adenoma/dysplasia had APC mutations. One was a frameshift mutation (4-bp deletion of TCTC spanning codons 1464 to 1465) observed in both the carcinoma and adenoma/dysplasia components, and the other was a frame shift mutation (1-bp insertion of A in a poly(A) tract spanning codons 1554 to 1556) detected only in the carcinoma component not in the adenoma/dysplasia component. There was no correlation between the presence of APC mutation and grade of dysplasia in flat dysplasia or adenoma (88% and 76% in low grade versus 61% and 80% in high grade, respectively, P = 0.4). The distribution of APC mutations is summarized in Figure 1
. Seventy-nine percent (50 of 63) of APC mutations were frameshifts (26 deletions and 24 insertions), and 21% (13 of 63) were nonsense point mutations resulting in truncation of the APC gene product. An insertion of A into the poly(A) tract at codons 1554 to 1556 was the most common (42%, 21 of 50) of the frameshift mutations. There were no significant associations between APC mutations and other clinicopathological parameters. No ß-catenin mutations were detected in adenocarcinomas (n = 74), adenomas (n = 10), or dysplasia (n = 14) without APC mutation.
|
|
|
MSI-H phenotype was more frequent in gastric adenoma/dysplasia associated with carcinoma (17%, 6 of 35) than in adenoma/dysplasia without carcinoma (3%, 2 of 75; P = 0.01) (Table 4)
. Two of 30 adenomas, but none of 45 flat dysplasias had MSI-H phenotype. MSI-H phenotype was also more frequent in intestinal-type adenocarcinoma (20%, 11 of 54) than in diffuse-type (0%, 0 of 20; P = 0.03). There was no difference in the frequency of MSI-L phenotype between gastric adenoma/dysplasia associated with carcinoma (9%, 3 of 35) and adenomas/dysplasia without carcinoma (9%, 7 of 75); or between intestinal type adenocarcinoma and diffuse type [6% (3 of 54) versus 5% (1 of 20), respectively].
|
|
There was an inverse correlation between the presence of MSI-H and the presence of APC gene mutations. APC gene mutations were present in six of nine (67%) gastric adenomas/dysplasias with MSI-L phenotype, but in none of the eight adenomas/dysplasia with MSI-H phenotype (P = 0.009) (Table 5)
. The three MSI-L adenomas/dysplasias without APC mutations were associated with adenocarcinomas. No APC mutations were detected in any of the 15 MSI+ (11 MSI-H and 4 MSI-L) gastric adenocarcinomas.
|
| Discussion |
|---|
|
|
|---|
The reason for lack of neoplastic progression in the majority of gastric adenomas and dysplastic lesions is not clear. APC gene mutations have been previously reported in up to 40% of gastric adenomas but only rarely in gastric adenocarcinomas.3,4,24-26,36,37 The presence of frequent somatic APC mutations in gastric adenoma but not in gastric carcinoma suggests that there is a different genetic pathway for the pathogenesis of adenoma and carcinoma. However, in previous studies only isolated adenomas and gastric carcinomas have been studied. Gastric adenoma/dysplasia lesions associated with adenocarcinomas have not been studied in detail for the presence of APC mutation.3,4,25,26,36 In most cases, the adenocarcinoma can be assumed to have arisen within the dysplasia or adenoma. If the APC gene plays any role in the pathogenesis of adenocarcinomas arising from pre-existing adenoma/dysplasia, APC gene mutations should be detected in both adenoma/dysplasia and adenocarcinoma components, similar to the frequency of APC gene mutations in adenomas or dysplasias without adenocarcinoma. Our study demonstrates that APC mutations are frequent in sporadic gastric adenomas and dysplasias, but only rarely in adenocarcinomas. This rare presence of APC mutations was true for both adenocarcinomas with or without associated adenoma/dysplasia. The findings in this study therefore strongly indicate that APC gene mutations play an important role in the pathogenesis of gastric adenoma and dysplasia, but have only a limited role in the pathogenesis of gastric adenocarcinomas. ß-catenin gene mutations have previously been reported in 5% (4 of 77) to 16% (7 of 43) of gastric adenocarcinomas from the Korean population.8,38 In contrast, we found no ß-catenin gene mutations in 54 intestinal and 20 diffuse type adenocarcinomas. The reason for this discrepancy is not clear.
Our results also suggest that APC gene mutation status could predict the biological behavior of individual gastric adenoma/dysplasia lesions (Figure 3)
. Gastric adenomas/dysplasias with APC gene mutations only rarely progress to adenocarcinoma. This corroborates the clinical observation that only 11 to 40% of adenomas/dysplasias can progress to carcinoma.29-31
This is contradictory to the role of the APC gene in colorectal carcinogenesis, in which it is regarded as a gatekeeper gene and is involved in the vast majority of colorectal carcinomas.39
Because we only sequenced the mutation cluster region of the APC gene, we cannot exclude APC mutations outside this region. It is possible that APC gene mutations in adenocarcinomas either associated or not associated with adenoma/dysplasia are different from sporadic gastric adenomas or dysplasias, and are not present within the mutation cluster region we have sequenced. However, the presence of only rare APC gene mutations in gastric carcinomas in previously published studies further corroborates our results.40
In addition, we have previously shown frequent somatic second-hit of APC genes in FAP-associated gastric fundic gland polyps.41
Foveolar dysplasia can present in up to 25% of FAP-associated fundic gland polyps, but rare occurrence of adenocarcinomas in FAP-associated fundic gland polyps. Therefore, APC gene mutations seem to have a different biological behavior in the stomach as compared to the colorectum, and gastric adenomas/dysplasia with APC mutations only rarely progress to adenocarcinomas.
|
Microsatellite instability (MSI) because of DNA replication errors has been widely observed in a variety of sporadic tumors in addition to tumors associated with hereditary nonpolyposis colorectal cancer syndrome because of germ line mutations in mismatch repair genes.45-48 MSI has been identified in 7 to 50% of gastric carcinomas with geographic variation in prevalence.49 We found MSI-H phenotype in 11% (8 of 75) of gastric adenomas/dysplasias and in 20% (11 of 54) of gastric intestinal type adenocarcinomas, which are similar to previously published results; 21% (13 of 63) in gastric adenomas and 30% (19 of 63) in gastric carcinomas from the Korean population.46 Similar to colorectal carcinomas, MSI-positive gastric carcinomas have distinct clinicopathological features including better prognosis, and prominent lymphoid infiltration. MSI-positivity is more common in intestinal type gastric carcinoma located in the antrum than in diffuse type carcinoma.50-53 In the present study, we found a higher prevalence of MSI-H phenotype in adenoma/dysplasia associated with adenocarcinoma than adenomas not associated with adenocarcinoma, as previously reported.54 Three of five MSI+ adenocarcinomas associated with adenoma/dysplasia components had a different allelic shift pattern between carcinoma and adjacent adenoma/dysplasia components. One explanation for this finding is that an adenocarcinoma acquires a different allelic size during progression of tumor from adenoma/dysplasia. This phenomenon has been described in MSI+ tumor cells.55 However, the possibility of adenocarcinoma arising de novo, and not from the pre-existing adenoma/dysplasia cannot be completely excluded. MSI+ colorectal and pancreatic carcinomas have a distinct genetic profile with wild-type K-ras and lack of p53 gene mutations.55-57 Similarly, MSI-H gastric adenocarcinomas or adenomas/dysplasias also correlated with the absence of APC gene mutations in our study. In contrast, MSI-L gastric adenomas/dysplasias had frequent APC mutations.
In conclusion, our results demonstrate that somatic mutation of the APC gene plays an important role in the pathogenesis of gastric adenoma and dysplasia but has limited role in neoplastic progression to adenocarcinoma. In contrast, gastric adenomas or dysplasias without APC mutations may have a different biological behavior, and are precursors of intestinal type of gastric adenocarcinomas. MSI-H can play an important role in a subset of adenocarcinomas arising from gastric adenomas/dysplasias without APC mutations.
| Footnotes |
|---|
Accepted for publication May 14, 2002.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
H. Tomita, Y. Yamada, T. Oyama, K. Hata, Y. Hirose, A. Hara, T. Kunisada, Y. Sugiyama, Y. Adachi, H. Linhart, et al. Development of Gastric Tumors in ApcMin/+ Mice by the Activation of the {beta}-Catenin/Tcf Signaling Pathway Cancer Res., May 1, 2007; 67(9): 4079 - 4087. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tajima, K. Yamazaki, R. Makino, N. Nishino, S. Aoki, M. Kato, K. Morohara, T. Kaetsu, and M. Kusano Gastric and intestinal phenotypic marker expression in early differentiated-type tumors of the stomach: clinicopathologic significance and genetic background. Clin. Cancer Res., November 1, 2006; 12(21): 6469 - 6479. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Rugge, G Bersani, R Bertorelle, G Pennelli, V M Russo, F Farinati, D Bartolini, M Cassaro, and V Alvisi Microsatellite instability and gastric non-invasive neoplasia in a high risk population in Cesena, Italy J. Clin. Pathol., August 1, 2005; 58(8): 805 - 810. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nabais, J. C. Machado, C. Lopes, R. Seruca, F. Carneiro, and M. Sobrinho-Simoes Patterns of {beta}-Catenin Expression in Gastric Carcinoma: Clinicopathological Relevance and Mutation Analysis International Journal of Surgical Pathology, January 1, 2003; 11(1): 1 - 9. [Abstract] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |